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In the Western world, cardiovascular disease (CVD) is the
leading cause of death in women. In Europe, 43% of men
die from CVD, compared with 54% in females, although
there has been a decline in the absolute number of deaths
from CVD in the past 30 years (in the Netherlands a 60%
decline in men and 52% in women with correction for age
distribution). Due to ageing of the population and the
longer life expectancy of women, it is to be expected that
even more women will die from CVD than men in the
future.
At younger age (pre-menopausal), females are more
susceptible to smoking-related damage when compared
with man, possibly due to the downregulation of oestrogen-
dependent vasodilatation of the endothelial wall of the
artery. As a consequence, smoking is the leading cause of
ischaemic heart disease at younger age in women. It is
known that menopause leads to a transition in hormonal
status and is associated with worsening of the cardiovascular
risk profile. After menopause the characteristic risk factors for
cardiovascular disease are similar in males and females;
however, the impact of these factors does differ between the
sexes. Especially hypertension, hypercholesterolaemia and
diabetes have a higher prevalence and impact in post-
menopausal women when compared with men.
However, besides the traditional overall risk factors,
women have female-specific risk factors which have a high
influence on the occurrence of CVD and their outcome after
coronary interventions. Women with a history of diabetes or
hypertensive disease in pregnancy (especially pre-eclampsia)
or with premature menopause are at increased risk for CVD
later in life. But, these factors are not taken into account in
clinicaltrialswhichleadstounderestimationoftheriskprofile
of females [1].
Furthermore, with respect to the pathophysiology,
women differ from men. Women have less obstructive
coronary artery disease along the entire spectrum of acute
coronary syndromes (ACS) and across all age groups. Even
in early stages females have a lower atheroma burden and
different plaque morphology than men. This phenomenon
is known as the ‘gender paradox’ as women do have
symptoms and die from myocardial infarction, but have
apparently less extensive disease. It is hypothesised that
different mechanisms play a role with respect to the
pathophysiology of atherosclerosis and the occurrence of
ACS in both sexes. In women, abnormal endothelial
function, difference in pre- and post-menopausal vascular
repair (oestrogen levels are changing), a higher incidence of
microvascular disease and a difference in autonomic
function (women have higher parasympathetic cardiac
activity while men have a higher sympathetic cardiac
activity) are mentioned as a possible explanation in this
matter [2].
In this issue of the journal, Breet et al. address the
potentially important issue of differences in platelet
physiology between the genders [3]. Previous studies
have suggested that women have a higher magnitude of
platelet reactivity when compared with men. In addition,
on-treatment platelet reactivity with aspirin is higher in
women. It is known that platelet reactivity plays a key role
in atherosclerosis and thrombus formation. Therefore,
(dual) antiplatelet therapy is the treatment of choice for
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and in those presenting with ACS. It is suggested that the
higher platelet reactivity in women might be one of the
explanations for the higher incidence of death in female
patients with CVD. Furthermore, studies have suggested
that women do not have comparable benefit from
antithrombotic therapy [4]. In their study, Breet at al.
compared the magnitude of on-treatment platelet reactivity
between genders in patients on dual antiplatelet therapy
undergoing elective coronary stenting [3]. This study was
a subanalysis of the POPular study (The Do Platelet
Function Assays Predict Clinical Outcomes in Clopidogrel
Pretreated Patients Undergoing Elective PCI study) which
was a prospective, observational study including consec-
utive patients with established coronary artery disease
scheduled for elective coronary stent implantation. It was
concluded that patients exhibiting a high on-treatment
platelet reactivity status may be at higher risk for adverse
events post-PCI. In the subanalysis, two platelet function
tests were used: the Light Transmission Aggregometry
(LTA) and the VerifyNow, two of the well-established tests
for platelet reactivity. As mentioned in prior studies, they
found that women (234 patients) had a higher magnitude
of on-aspirin and on-clopidogrel platelet reactivity at
baseline compared with men (717 patients), even after
adjustment for potential confounders in multivariate
analysis. However, the occurrence of the composite
endpoint (death, myocardial infarction, stent thrombosis
and stroke) was similar between the two groups. Conse-
quently, they concluded that with respect to this result it
seemed unlikely that the difference in platelet reactivity
accounts for a worse prognosis in women. Although this
study was well designed and performed by a highly
experienced research group, a few comments can be
made [5].
In this study, women have a higher magnitude of on-
aspirin and on-clopidogrel platelet reactivity but the
absolute difference in clinical endpoints is rather small
and therefore does not seem to be clinically relevant (22.4±
11.4% female vs. 19.8±11.1% male on-aspirin LTA and
59.6±13.2% female vs. 56.9±14.6% male on-clopidogrel
LTA). These findings are not new and large randomised
secondary prevention trials have demonstrated a worse
outcome in women on dual antiplatelet therapy (CURE,
CAPRIE, CREDO trials). Interestingly, this outcome seems
to change somewhat in favour of women when treated with
the newer antiplatelet drugs as prasugrel and ticagrelor
(PLATO, TRITON trials). This suggests that the biological
availability of the drug plays an important role. As
hormonal changes influence the gastrointestinal uptake of
antiplatelets and also their metabolism, these new drugs
seem to be of clinical importance.
Furthermore, the study is based on a subgroup analysis
using a different endpoint and consequently is not powered
for comparison of the magnitude of on-treatment platelet
reactivity between genders.
Finally, the study does not indicate whether measur-
ing on-treatment platelet reactivity in patients receiving
antiplatelet therapy is helpful and whether women might
particularly benefit from such measurements. According
to the recent ESC nSTE-ACS guidelines, personalised
antiplatelet treatment has yet not arrived in the clinical
arena, as platelet function testing received a IIb
recommendation [6].
In conclusion, the data reported in this study are not
sufficient to answer the questions with respect to the
relation between gender, the occurrence of clinical end-
points and platelet reactivity in patients undergoing elective
PCI and using dual antiplatelet therapy. The higher platelet
activity in females and the possible consequences is hard to
understand and further large randomised clinical trials with
the new-generation antiplatelet therapy are needed to
establish their role in coronary artery disease. However,
this study again points out clearly that women are hard to
control.
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